Innoviva Share Price (NASDAQ: INVA)

$19.84

▲

-0.09

(-0.45%)

Live

Last updated on August 28, 2025 at 1:29 am IST

$₹

Check the interactive Innoviva Stock chart to analyse performance

Innoviva stock performance

as on August 28, 2025 at 1:29 am IST

Today's Low:$19.84
Today's High:$20.25
$19.84
0.0%
Downside
Day's Volatility :2.02%
Upside
2.02%
52 Weeks Low:$16.67
52 Weeks High:$22.00
$19.84
15.98%
Downside
52 Weeks Volatility :24.23%
Upside
9.82%

Innoviva Stock Returns

Period	Innoviva, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	4.24%	3.7%	0.0%
6 Months	11.34%	-6.9%	0.0%
1 Year	4.29%	-11.9%	0.0%
3 Years	48.4%	7.7%	-6.9%

Innoviva, Inc. Key Stats

Check Innoviva key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$19.93
Open	$20.19
Today's High	$20.25
Today's Low	$19.81
Market Capitalization	$1.2B
Today's Volume	$698.4K
52 Week High	$22.0
52 Week Low	$16.67
Revenue TTM	$370.2M
EBITDA	$206.9M
Earnings Per Share (EPS)	$0.57
PE Ratio	34.67
Profit Margin	10.44%
Quarterly Earnings Growth YOY	-0.63%
Return On Equity TTM	5.6%

Stock Returns calculator for Innoviva Stock including INR - Dollar returns

The Innoviva stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Innoviva investment value today

Current value as on today

₹1,08,493

Returns

₹8,493

(+8.49%)

Returns from Innoviva Stock

₹3,820 (+3.82%)

Dollar Returns*

₹4,673 (+4.67%)

Indian investors sentiment towards Innoviva Stock

-59%

Period: Jul 27, 2025 to Aug 26, 2025. Change in 30 Days versus previous period

Search interest for Innoviva Stock from India on INDmoney has decreased by -59% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Innoviva, Inc.

Name
Holdings %
Name
Holdings %
BlackRock Inc
14.62%
Vanguard Group Inc
11.39%
Renaissance Technologies Corp
7.23%
Dimensional Fund Advisors, Inc.
6.81%
Franklin Resources Inc
4.49%
Sarissa Capital Management LP
4.47%

Analyst Recommendation on Innoviva Stock

Rating

Trend

Sell

0%Buy

50%Hold

50%Sell

Based on 6 Wall street analysts offering stock ratings for Innoviva(by analysts ranked 0 to 5 stars)

Innoviva Share Price Target

What analysts predicted

Upside of 106.65%

Target:

$41.00

Current:

$19.84

Innoviva share price target is $41.00, a slight Upside of 106.65% compared to current price of $19.84 as per analysts' prediction.

Innoviva Stock Insights

Price Movement
In the last 7 days, INVA stock has moved down by -0.1%
Increasing Revenue
Revenue is up for the last 2 quarters, 88.63M → 100.28M (in $), with an average increase of 11.6% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -46.58M → 63.68M (in $), with an average increase of 173.1% per quarter
INVA vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 61.0% return, outperforming this stock by 56.7%
INVA vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 113.9% return, outperforming this stock by 64.4%
Price to Sales
ForINVA every $1 of sales, investors are willing to pay $3.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.7 for every $1 of sales.

Innoviva, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$261.0M	↑ 0.0%
Net Income	$157.3M	↓ 60.19%
Net Profit Margin	60.26%	↓ 91.1%

	FY20	Y/Y Change
Revenue	$336.8M	↑ 29.03%
Net Income	$224.4M	↑ 42.67%
Net Profit Margin	66.63%	↑ 6.37%

	FY21	Y/Y Change
Revenue	$391.9M	↑ 16.35%
Net Income	$265.9M	↑ 18.47%
Net Profit Margin	67.84%	↑ 1.21%

	FY22	Y/Y Change
Revenue	$331.3M	↓ 15.45%
Net Income	$213.9M	↓ 19.53%
Net Profit Margin	64.56%	↓ 3.28%

	FY23	Y/Y Change
Revenue	$310.5M	↓ 6.3%
Net Income	$179.7M	↓ 15.99%
Net Profit Margin	57.89%	↓ 6.67%

	FY24	Y/Y Change
Revenue	$358.7M	↑ 15.54%
Net Income	$23.4M	↓ 86.98%
Net Profit Margin	6.52%	↓ 51.37%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$81.0M	↓ 9.32%
Net Income	$36.5M	↓ 40.63%
Net Profit Margin	45.13%	↓ 23.8%

	Q2 FY24	Q/Q Change
Revenue	$103.4M	↑ 27.67%
Net Income	$-34.7M	↓ 194.94%
Net Profit Margin	-33.56%	↓ 78.69%

	Q3 FY24	Q/Q Change
Revenue	$89.5M	↓ 13.4%
Net Income	$1.2M	↓ 103.5%
Net Profit Margin	1.36%	↑ 34.92%

	Q4 FY24	Q/Q Change
Revenue	$91.8M	↑ 2.57%
Net Income	$20.3M	↑ 1576.17%
Net Profit Margin	22.15%	↑ 20.79%

	Q1 FY25	Q/Q Change
Revenue	$88.6M	↓ 3.46%
Net Income	$-46.6M	↓ 329.12%
Net Profit Margin	-52.56%	↓ 74.71%

	Q2 FY25	Q/Q Change
Revenue	$100.3M	↑ 13.15%
Net Income	$63.7M	↓ 236.72%
Net Profit Margin	63.51%	↑ 116.07%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$261.0M	↑ 0.0%

	FY20	Y/Y Change
Profit	$336.8K	↓ 99.87%

	FY21	Y/Y Change
Profit	$391.9M	↑ 116251.84%

	FY22	Y/Y Change
Profit	$317.5M	↓ 18.97%

	FY23	Y/Y Change
Profit	$261.1M	↓ 17.79%

	FY24	Y/Y Change
Profit	$322.1M	↑ 23.38%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$60.0M	↓ 9.24%

	Q2 FY24	Q/Q Change
Profit	$85.0M	↑ 41.53%

	Q3 FY24	Q/Q Change
Profit	$79.5M	↓ 6.41%

	Q4 FY24	Q/Q Change
Profit	$78.1M	↓ 1.81%

	Q1 FY25	Q/Q Change
Profit	$79.8M	↑ 2.19%

	Q2 FY25	Q/Q Change
Profit	$89.7M	↑ 12.41%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$257.5M	↑ 15.18%
Investing Cash Flow	$-18.0M	↓ 611.59%
Financing Cash Flow	$-23.8M	↓ 90.01%

	FY20	Y/Y Change
Operating Cash Flow	$313.1M	↑ 21.62%
Investing Cash Flow	$-314.9M	↑ 1649.36%
Financing Cash Flow	$-29.8M	↑ 25.27%

	FY21	Y/Y Change
Operating Cash Flow	$363.8M	↑ 16.19%
Investing Cash Flow	$43.7M	↓ 113.88%
Financing Cash Flow	$-452.5M	↑ 1419.21%

	FY22	Y/Y Change
Operating Cash Flow	$201.7M	↓ 44.55%
Investing Cash Flow	$-56.6M	↓ 229.53%
Financing Cash Flow	$-55.6M	↓ 87.72%

	FY23	Y/Y Change
Operating Cash Flow	$141.1M	↓ 30.07%
Investing Cash Flow	$-66.8M	↑ 17.88%
Financing Cash Flow	$-171.8M	↑ 209.24%

	FY24	Y/Y Change
Operating Cash Flow	$188.7M	↑ 33.76%
Investing Cash Flow	$-63.8M	↓ 4.46%
Financing Cash Flow	$-13.5M	↓ 92.17%

Q1 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$37.0M	↑ 11.4%
Investing Cash Flow	$-43.0M	↑ 735.53%
Financing Cash Flow	$-9.2M	↓ 37.18%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$48.7M	↑ 11.36%
Investing Cash Flow	$-5.3M	-
Financing Cash Flow	$211.0K	↓ 104.16%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$59.2M	↑ 21.68%
Investing Cash Flow	$-15.5M	↑ 193.7%
Financing Cash Flow	$573.0K	↑ 171.56%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$48.6M	↓ 17.93%
Investing Cash Flow	$-34.7M	↑ 124.02%
Financing Cash Flow	$183.0K	↓ 68.06%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$44.1M	↓ 9.35%
Investing Cash Flow	$33.1M	↓ 195.52%
Financing Cash Flow	$1.2M	↑ 581.42%

Innoviva Technicals Summary

Sell

Neutral

Buy

Innoviva is currently in a neutral trading position according to technical analysis indicators.

Innoviva, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Innoviva, Inc.	7.5%	11.34%	4.29%	48.4%	70.93%
Regeneron Pharmaceuticals, Inc.	5.16%	-16.9%	-51.12%	-0.89%	-2.51%
Beone Medicines Ltd	4.54%	18.87%	52.28%	84.02%	26.72%
Vertex Pharmaceuticals Incorporated	-16.02%	-19.22%	-19.42%	37.43%	43.36%
Alnylam Pharmaceuticals, Inc.	38.9%	84.99%	60.96%	115.82%	243.29%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Innoviva, Inc.	34.67	34.67	0.43	1.8	0.06	0.09	NA	11.34
Regeneron Pharmaceuticals, Inc.	14.86	14.86	1.21	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.29	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.64	27.64	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Innoviva, Inc.	Sell	$1.2B	70.93%	34.67	10.44%
Regeneron Pharmaceuticals, Inc.	Buy	$62.5B	-2.51%	14.86	31.37%
Beone Medicines Ltd	NA	$38.3B	26.72%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$99.7B	43.36%	27.64	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.2B	243.29%	NA	-12.96%

About Innoviva, Inc.

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline), a tetracycline class antibacterial for the treatment of complicated intra-abdominal infections in adults; XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia; and ZEVTERA, a cephalosporin antibacterial for the treatment of adult patients with staphylococcus aureus bloodstream infections, adult patients with acute bacterial skin and skin structure infections, and adult and pediatric patients with community-acquired bacterial pneumonia. Its development pipeline includes Zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Organization	Innoviva
Employees	127
CEO	Mr. Pavel Raifeld C.F.A.
Industry	Health Technology

Key Management of Innoviva, Inc.

Name	Title
Mr. Pavel Raifeld C.F.A.	CEO & Director
Mr. Stephen Basso M.B.A.	Chief Financial Officer
Ms. Marianne Zhen CPA	Chief Accounting Officer & Secretary
Ms. Marcie Cain	Chief People Officer
Ms. Patricia M. Drake	Chief Commercial Officer-Innoviva Specialty Therapeutics, Inc.
Dr. David Altarac M.D., MPA	Chief Medical Officer of IST

Important FAQs about investing in INVA Stock from India :

What is Innoviva share price today?

Innoviva share price today is $19.84 as on August 28, 2025 at 1:29 am IST. Innoviva share today touched a day high of $20.25 and a low of $19.84.

What is the 52 week high and 52 week low for Innoviva share?

Innoviva share touched a 52 week high of $22.00 and a 52 week low of $16.67. Innoviva stock price today i.e. August 28, 2025 at 1:29 am IST is trending at $19.84, lower by 9.82% versus the 52 week high.

How to invest in Innoviva Stock (INVA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Innoviva on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Innoviva Shares that will get you 0.0756 shares as per Innoviva share price of $19.84 per share as on August 28, 2025 at 1:29 am IST.

What is the minimum amount required to buy Innoviva Stock (INVA) from India?

Indian investors can start investing in Innoviva (INVA) shares with as little as ₹87.86 or $1 (as of August 27, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹878.60 in Innoviva stock (as per the Rupee-Dollar exchange rate as on August 27, 2025). Based on Innoviva share’s latest price of $19.84 as on August 28, 2025 at 1:29 am IST, you will get 0.5040 shares of Innoviva. Learn more about fractional shares .

What are the returns that Innoviva has given to Indian investors in the last 5 years?

Innoviva stock has given 70.93% share price returns and 18.89% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?